Novartis drops Novo's NN622

Novartis (NVS; SWX:NOVN) ended a July deal with Novo Nordisk (NVO) to commercialize NVO's Type II diabetes treatment NN622, a PPAR (peroxisome proliferator-activated receptor) alpha and gamma antagoni...